Immunotherapy and Survival in NSCLC: Does Obesity Matter?
Aug 12, 2024 · Among patients with overweight or obesity, frontline immunotherapy for advanced non–small cell lung cancer (NSCLC) was not associated with a survival benefit compared with …
FDA Approves Zongertinib for HER2-Mutated NSCLC - Medscape
Aug 8, 2025 · The FDA has granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.) for certain adults with unresectable or metastatic …
Tarlatamab Approved for Advanced Small Cell Lung Cancer
Jan 3, 2025 · It is less common than non-small cell lung cancer and spreads more quickly. The prognosis for patients with extensive-stage SCLC is poor, with a 5-year survival rate of 10%.
Measuring Expectations: Real-World Survival With Osimertinib
Aug 28, 2024 · In a real-world population of patients with EGFR-mutant advanced lung cancer, overall survival was much worse in patients who would not have been eligible for the pivotal …
Lung Cancer - Medscape
Lung cancer is the leading cause of cancer death among both men and women, and is the top cause of smoking-related mortality.
Telisotuzumab Vedotin Approved for NSCLC - Medscape
May 15, 2025 · The antibody-drug conjugate is approved for previously treated advanced NSCLC patients with high c-Met protein overexpression.
First Drug for Lung Cancer With KRAS Mutation Gains FDA …
May 28, 2021 · "Patients with non-small cell lung cancer who have progressed beyond first-line treatment face a poor prognosis and have limited treatment options available to them.
Toxicity Linked to Longer Survival in Patients With NSCLC
Jan 30, 2024 · Patients who have immune-related adverse events when treated for non–small cell lung cancer (NSCLC) may live longer than those without these complications, according to a …
NSCLC Survival Benefit Seen With EGFR-TKI + Chemo - Medscape
Sep 7, 2025 · Median PFS benefit was just over 3 months in patients with EGFR-mutant NSCLC who had tumor suppressor gene co-mutations.
Record Survival Seen With Tarlatamab Maintenance in SCLC
Sep 16, 2025 · In a phase 1b trial, tarlatamab plus an anti-PD-L1 in first-line maintenance achieves a median survival of more than 2 years in extensive-stage small cell lung cancer.